HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Dennert, G. Articles by Lennox, E. S. Search for Related Content PubMed Articles by Dennert, G. Articles by Lennox, E. S.

Phagocytic Cells as Effectors in a Cell-Mediated Immunity System¹

The Salk Institute for Biological Studies, The Armand Hammer Center for Cancer Biology, San Diego, California 92112

Abstract

Cell-mediated immunity, using a xenogeneic system, i.e., mouse spleen cells attacking chicken erythrocytes (CRBC) is studied.

In this system target cell lysis by spleen cells from immunized animals is complement independent, hence cell-mediated. It is specific because trinitrophenyl-(TNP) sensitized spleens lyse TNP-CRBC but not CRBC. CRBC-sensitized thymus-derived (T) lymphocytes cooperate with bone marrow-derived lymphocytes in induction of CRBC plaque-forming cells but cannot lyse CRBC as target. However, anti-CRBC antibody at concentrations too low to be detected by complement dependent lysis do induce cytotoxicity to CRBC in spleen cell suspensions containing T cells as well as in spleen cell suspensions depleted of T cells. Anti- serum absorbed to remove non-anti- antibody does not abrogate the cytotoxicity of immune spleen cells. These results indicate that the effector cell in this system is not a -antigen-bearing T lymphocyte. The effector cell is abundant in spleen and in the peritoneal cavity but not in lymph nodes of normal animals: it is bone marrow-derived, radiation resistant, and sticks to siliconized glass bead columns. Since, in addition, the effector cell can be separated from other spleen cells by treatment with carbonyl iron powder and a magnet, it is, we suggest, a phagocytic cell.

Footnotes

¹ Financial support was provided by the National Institutes of Health via Research Grant AI 06544 from the National Institute of Allergy and Infectious Diseases, and from Contract 72-E-3207 from the National Cancer Institute. Funds were also provided to the Salk Institute by Dr. Armand Hammer and from a grant provided by the Edna McConnell Clark Foundation.

² Gunther Dennert is a Fellow of the Edna McConnell Clark Foundation.

³ Edwin Lennox was partially supported by a grant from The Western Institute for Cancer and Leukemia Research.